As the coronavirus pandemic continues, a recent article from the BBC shows medical experts confirming up to 30% of patients who are seriously ill with COVID-19 are developing thrombosis. 

With the diversity and availability of POCT continuing to rise, a new generation of tests is breaking down the barriers between laboratories and patients.

Hart Biologicals has recently announced the addition of its sixth product, Arachidonic Acid MEA, to its MEA range of platelet aggregation testing reagents.

Hart Biologicals is continuing to get supplies of its products to partners overseas, as the UK enters a further period of restrictions due to the coronavirus pandemic. 

As the NHS faces up to the unprecedented challenges posed by the threat of COVID-19, many other patients not affected by the coronavirus still rely on the services it provides for vital preventative care.  

As a company, Hart Biologicals is constantly championing the important role apprentices can play across departments throughout its organisation.  

As the impact of the current crisis widens around the world, Hart Biologicals continues a programme of stepping up to meet the challenge that the coronavirus poses. 

As the outbreak of the coronavirus COVID-19 makes a significant impact on the lives of everyone in the UK, Europe and in many parts of the world, Hart Biologicals is stepping up its efforts to ensure all customer needs and expectations are being met. 

At Hart Biologicals, we research and manufacture kits for the detection of blood and platelet disorders including that of systematic lupus erythematosus commonly known as Lupus or SLE. 

As the World Health Organisation labelled the outbreak of the coronavirus COVID-19 as a pandemic, the Hartlepool-based healthcare manufacturer has stepped up its campaign of vigilance to keep its customers and employees as safe as possible. 


Hart Biologicals has recently launched two new products in their MEA range to monitor and test the platelet response of patients. 

Two members of the Hart Biologicals QA team have attended the 3rd Annual European Medical Device and Diagnostic Quality Management Conference in Brussels.